Chemical Property of Probucol
Chemical Property:
- Appearance/Colour:White Solid
- Vapor Pressure:1.46E-12mmHg at 25°C
- Melting Point:126-128 °C
- Refractive Index:1.573
- Boiling Point:546.7 °C at 760 mmHg
- PKA:10.27±0.70(Predicted)
- Flash Point:264.9 °C
- Density:1.07 g/cm3
- Storage Temp.:Desiccate at +4°C
- Solubility.:Chloroform (Slightly), Ethyl Acetate (Slightly)
- XLogP3:11.3
- Hydrogen Bond Donor Count:2
- Hydrogen Bond Acceptor Count:4
- Rotatable Bond Count:8
- Exact Mass:516.30957312
- Heavy Atom Count:35
- Complexity:583
- Purity/Quality:
-
99.9% *data from raw suppliers
Probucol *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
SDS file from LookChem
Total 1 MSDS from other Authors
Useful:
- Canonical SMILES:CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)SC(C)(C)SC2=CC(=C(C(=C2)C(C)(C)C)O)C(C)(C)C
- Recent ClinicalTrials:The Effect of InTensive Statin in Ischemic Stroke With inTracranial Atherosclerotic Plaques
- Recent NIPH Clinical Trials:None
-
Description
Probucol is a kind of bis-phenol antioxidant with anti-hyperlipidemic activity. It had been initially developed for the treatment of coronary artery disease. However, its clinical trials were stopped after people found that it could lower the HDL and LDL cholesterol in patients of a history of heart disease. Probucol exerts its effect through accelerating the fractional rate of low-density (LDL) catabolism which is in the final pathway of cholesterol elimination inside the body. It may also inhibit the early stage of cholesterol biosynthesis and dietary cholesterol absorption.
-
Uses
antihyperlipidemic Probucol is an antilipemic. anti-hyperlipoproteinemic An antioxidant, anti-inflammatory, and hypocholesterolemic agent which inhibits atherogenesis in murine models.
-
Biological Functions
Probucol (Lorelco) is a hypocholesterolemic drug with
few side effects that modestly (15–30%) decreases elevated
plasma LDL cholesterol levels. The marginal LDL-lowering action plus reports that it can lower
HDL cholesterol resulted in its discontinuation as a
hypocholesterolemic drug. However, it still may reduce
the risk of CHD because it is a powerful antioxidant.
The oxidation hypothesis of atherosclerosis states
that oxidation of lipids in LDL is required for LDL uptake
by macrophages and smooth muscle cells in the intima
of arteries, leading to their transformation to foam cells, an early event in atherogenesis. A recent clinical
trial reported that use of probucol decreased the rate of
restenosis of coronary arteries by 50% in patients who
underwent angioplasty. Fluvastatin also has potent antioxidant
properties that may contribute to its antiatherosclerotic
effects.These findings suggest that reducing
high plasma lipids may not be the only approach to retarding
the progression of atherosclerosis and decreasing
the risk of coronary heart disease.
